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Endothelial Dysfunction and Low-Grade Inflammation
Explain Much of the Excess Cardiovascular Mortality
in Individuals With Type 2 Diabetes
The Hoorn Study
Jolien de Jager, Jacqueline M. Dekker, Adriaan Kooy, Piet J. Kostense, Giel Nijpels, Rob J. Heine,
Lex M. Bouter, Coen D.A. Stehouwer
Objective—The mechanisms responsible for the increased cardiovascular disease risk that accompanies type 2 diabetes
(T2D) remain poorly understood. It is commonly held that endothelial dysfunction and low-grade inflammation can
explain, at least in part, why deteriorating glucose tolerance is associated with cardiovascular disease. However, there
is no direct evidence for this contention.
Methods and Results—In this population-based study (n631), T2D was cross-sectionally associated with both
endothelial dysfunction and low-grade inflammation, whereas impaired glucose metabolism (IGM) was associated only
with low-grade inflammation. These findings were independent of other risk factors that accompany T2D or IGM.
During a follow-up of 11.7 years (median; range 0.5 to 13.2 years), low-grade inflammation was associated with a
greater risk of cardiovascular mortality (hazard ratio, 1.43 [95% CI, 1.17 to 1.77] per 1 SD difference). For endothelial
dysfunction, the association with cardiovascular mortality was stronger in diabetic (hazard ratio, 1.87 [95% CI, 1.43 to
2.45]) than in nondiabetic individuals (hazard ratio, 1.23 [95% CI, 0.86 to 1.75]; P interaction0.06). Finally,
T2D-associated endothelial dysfunction and low-grade inflammation explained 43% of the increase in cardiovascular
mortality risk conferred by T2D.
Conclusions—These data emphasize the necessity of randomized controlled trials of strategies that aim to decrease
cardiovascular disease risk by improving endothelial function and decreasing low-grade inflammation, especially for
T2D patients. (Arterioscler Thromb Vasc Biol. 2006;26:1086-1093.)
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Up to 75% of individuals with type 2 diabetes (T2D) will dieof cardiovascular disease.1 However, the mechanisms re-
sponsible for the high cardiovascular disease risk that accompa-
nies T2D and possibly impaired glucose metabolism (IGM; ie,
impaired fasting glucose and (or) impaired glucose tolerance)2
remain poorly understood. There is strong evidence that conven-
tional risk factors, such as hypertension, obesity, and dyslipid-
emia, cannot fully explain the high cardiovascular disease risk
associated with deteriorated glucose tolerance.3
It is commonly held that endothelial dysfunction and
low-grade inflammation, 2 key features in the pathophysiol-
ogy of atherothrombosis,4–7 can explain, at least in part, why
deteriorated glucose tolerance is associated with cardiovas-
cular disease.2,8 However, there is no direct evidence for this
contention, and several important issues have remained un-
resolved. First, it is not clear to what extent the associations
of IGM and T2D on the one hand with endothelial dysfunc-
tion and low-grade inflammation on the other are independent
of other risk factors associated with deteriorated glucose
tolerance. Second, it is not known whether associations of
endothelial dysfunction and low-grade inflammation with
cardiovascular disease are independent of other conventional
cardiovascular risk factors and indicators, nor to what extent
these associations overlap or represent distinct pathways. If
these pathways are distinct, then associations of endothelial
dysfunction and low-grade inflammation with cardiovascular
disease will be expected to be mutually independent. Finally,
it is not known to what extent associations of IGM and T2D
with cardiovascular disease are in fact accounted for by IGM-
and T2D-associated endothelial dysfunction and low-grade
inflammation.
We addressed these questions in the Hoorn Study, a
prospective population-based cohort study of glucose toler-
ance and cardiovascular disease.9,10
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Materials and Methods
General Study Design
This study was part of the Hoorn Study, a population-based cohort
study of glucose tolerance and cardiovascular disease in a white
population in Hoorn, The Netherlands, of which the baseline
measurement was performed from October 1989 to February
1992.9,10 Briefly, a random sample of all men and women 50 to 75
years of age was drawn from the municipal population registration
office of Hoorn; 2484 individuals participated (response rate 71%).
The present study population is an age-, sex-, and glucose-tolerance–
stratified random subsample (n631; response rate 89%) in whom
an extensive investigation of diabetes complications was per-
formed.9,10 For the present analyses, we used the 1999 World Health
Organization criteria and classified individuals as having normal
glucose metabolism (NGM), IGM, or T2D based on 2 glucose
tolerance tests.11
The Hoorn Study was approved by the ethical review committee
of the VU University Hospital. Written informed consent was
obtained from all participants.
Baseline Investigations
We considered plasma levels of von Willebrand factor (vWF) and
soluble vascular adhesion molecule-1 (sVCAM-1) as markers of
endothelial function12–14 and plasma levels of C-reactive protein
(CRP) and soluble intercellular adhesion molecule-1 (sICAM-1) as
markers of low-grade inflammation.15,16 Microalbuminuria was not
used as a marker of endothelial function because we have shown
previously that microalbuminuria in the Hoorn Study is heteroge-
neous in terms of its association with endothelial dysfunction.17
Markers of Endothelial Dysfunction and
Low-Grade Inflammation
Concentrations of vWF, sVCAM-1, CRP, and sICAM-1 were
assessed in deep frozen (70°C) heparin plasma samples. vWF,
sVCAM-1, and sICAM-1 were estimated in duplicate by
ELISA.18–20 For vWF and sVCAM-1, no plasma samples were
available for 21 subjects. Concentrations of CRP were measured
with a highly sensitive sandwich enzyme immunoassay, as described
previously.18 For CRP and sICAM-1, no plasma samples were
available for 23 subjects.
Other Measurements
We obtained an ankle-brachial blood pressure index (n631) and a
resting ECG (n625).9,10 Subjects were classified as having cardio-
vascular disease when they had a history of myocardial infarction or
had an ECG with a Minnesota code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3,
or 7.1 or had undergone coronary bypass surgery or angioplasty, or
had an ankle-brachial pressure index 0.9 in either leg, or had
undergone a peripheral arterial bypass or nontraumatic amputation.
In addition, we obtained data on blood pressure, weight, height, body
mass index, waist-to-hip ratio, glycohemoglobin, serum creatinine,
homocysteine, total cholesterol, high-density lipoprotein (HDL)
cholesterol, triglycerides, smoking habits, and the use of medication.
Low-density lipoprotein (LDL) cholesterol was calculated by the
Friedewald formula21 except when the triglyceride level was
4.55 mmol/L (n23). Hypertension was defined as a blood
pressure 140 mm Hg systolic and/or 90 mm Hg diastolic and/or
the current use of antihypertensive medication. Subjects were clas-
sified as current cigarette smokers or nonsmokers. The glomerular
filtration rate was calculated according to Levey et al.22
Follow-Up
For each subject, we determined whether or not death had occurred
during follow-up, and if so, the date at which death occurred. Data on
the subjects’ vital status on January 1, 2003, were collected from the
mortality register of the municipality of Hoorn. Of 51 subjects who
had moved out of town, information on vital status was obtained
from the new local municipalities. For all subjects who had died, the
cause of death was extracted from the medical records of the general
practitioner and the hospital of Hoorn, and classified according to the
ninth edition of the International Classification of Diseases.23 Car-
diovascular mortality was defined as codes 378 and 390 to 459.
Information on cause of death could not be obtained for 33 (19%) of
the deceased subjects, and 1 subject was lost to follow-up.
Statistical Analyses
Because markers of endothelial dysfunction and inflammatory ac-
tivity show marked intraindividual (day-to-day) variation and be-
cause we measured these markers only once, the associations (if any)
of endothelial dysfunction and inflammatory activity with other
variables will tend to be underestimated. As a result of this, statistical
power will be diminished. To address this concern, we created mean
SD scores (z scores) for markers of endothelial dysfunction and
chronic low-grade inflammation and used these in regression anal-
yses as described below. For each subject, each variable was
expressed as SDs of difference from the population mean, which was
calculated using all available data on the separate markers (n608
and 610 [of 631] for the endothelial dysfunction and inflammation z
scores, respectively). The z scores were calculated as the mean of
these SD scores as follows: (1) endothelial dysfunction z
score[vWF  sVCAM-1]/2 and (2) inflammation z score[CRP
 sICAM-1]/2.
To assess to what extent the associations of T2D and IGM on the
one hand with endothelial dysfunction and low-grade inflammation
on the other were independent of other risk factors known to be
associated with deteriorated glucose tolerance, we performed linear
regression analyses. Endothelial dysfunction or inflammation z
scores were entered as dependent variables and T2D and IGM as
independent variables, with adjustment for potential confounders.
Results are described as regression coefficients () with 95% CIs.
To assess associations of markers of endothelial dysfunction and
low-grade inflammation with risks of cardiovascular and all-cause
mortality, we performed Kaplan–Meier and Cox proportional haz-
ards multiple regression analyses. Because of the stratification
procedure, we first adjusted for age, sex, and glucose tolerance status
in all models and, subsequently, for other potential confounders.
Variables measured on a continuous scale were used as such in the
regression models except for levels of sVCAM-1, CRP, and systolic
and diastolic blood pressure because of their nonlinear association
with mortality. Therefore, a high level of sVCAM-1 was defined as
in the upper tertile (1485 ng/mL); data on CRP were log-
transformed before analysis; and systolic and diastolic blood pres-
sure were defined as high (140 mm Hg and 90 mm Hg, respec-
tively) or low. In spite of the nonlinear association of sVCAM-1
(all-cause) and CRP (both all-cause and cardiovascular) with mor-
tality, additional analysis showed that associations between the z
scores and mortality were nevertheless best described as linear. To
evaluate a possible interaction between glucose tolerance status and
endothelial dysfunction or low-grade inflammation, Cox regression
analyses were performed with glucose tolerance status, the endothe-
lial dysfunction or inflammation z score, their product term, age, and
sex in the model. A significant hazard ratio for the product term was
considered indicative for interaction of glucose tolerance status with
either low-grade inflammation or endothelial dysfunction. Results
are described as relative risks (hazard ratios) with 95% CIs.
To assess to what extent associations of T2D and IGM with
cardiovascular mortality could in fact be explained by T2D- and
IGM-associated endothelial dysfunction and low-grade inflamma-
tion, we performed Cox regression analyses without and with
adjustments for the endothelial dysfunction and inflammation z
scores and without and with potential interaction terms. Percentages
explained were calculated using the regression coefficients instead of
hazard ratios because of the logarithmic character of the hazard ratio.
All models were fitted comparing T2D and IGM to NGM, and T2D
to IGM separately.
Two-sided P values 0.05 were considered statistically signifi-
cant except for the interaction analyses, where P values 0.10 were
used.
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Results
The median duration of follow-up was 11.7 years (range 0.5
to 13.2 years). After follow-up, 174 (55 NGM, 43 IGM, and
76 T2D) of the 631 subjects had died, of whom 66 (38%; 17
NGM, 16 IGM, and 33 T2D) had died of cardiovascular
disease. Table 1 shows the baseline characteristics of the
study population according to glucose tolerance status.
Glucose Tolerance Status Is Associated With
Endothelial Dysfunction and
Low-Grade Inflammation
Table 2 and Figure I (available online at http://atvb.ahajournal-
s.org) show that T2D was significantly associated with both
endothelial dysfunction and low-grade inflammation, whereas
IGM was associated only with low-grade inflammation.
Higher Levels of Markers of Endothelial
Dysfunction and Low-Grade Inflammation Are
Associated With Greater Mortality Risks
Figure 1 and Table 3 show that in general, higher levels of
markers of endothelial dysfunction, low-grade inflamma-
tion, and their z scores were associated with greater
mortality risks. For example, the hazard ratio of cardio-
vascular and all-cause mortality associated with the in-
flammation z score were 1.43 (1.17 to 1.77) and 1.27 (1.10
to 1.47) per SD difference. For endothelial dysfunction, the
associations with cardiovascular and all-cause mortality
were stronger in diabetic than in nondiabetic individuals (P
interaction0.064 and 0.028; Table 3). For example, the
cardiovascular mortality hazard ratio associated with the
endothelial dysfunction z score was 1.87 (1.43 to 2.45) for
diabetic individuals compared with 1.23 (0.86 to 1.75) in
nondiabetic individuals. For all-cause mortality, the hazard
ratio was 1.41 (1.16 to 1.72) in diabetic individuals and
1.09 (0.87 to 1.36) in nondiabetic individuals. Results were
similar when individual markers were used instead of the
endothelial dysfunction and inflammation z scores (data
not shown). Table I shows that adjustment for potential
confounders (hypertension, smoking, LDL cholesterol,
HDL cholesterol, triglycerides, previous cardiovascular
disease, body mass index, homocysteine, and glomerular
filtration rate) did not markedly change the associations of
the endothelial dysfunction and inflammation z scores with
cardiovascular and all-cause mortality.
TABLE 1. Baseline Characteristics of the Study Population According to Glucose Tolerance Status
NGM IGM T2D P (trend)
No. (males/females) 258 (126/132) 179 (91/88) 194 (87/107)
Conventional risk factors
Age, y 637 647 667 0.001
Hemoglobin A1c, % of hemoglobin 5.30.5 5.60.5 7.11.8 0.001
Hypertension, % 25 43 55 0.001
Diastolic blood pressure, mm Hg 8110 8410 8310 0.05
Systolic blood pressure, mm Hg 13318 14220 14419 0.001
Current smokers, % 30 22 24 0.15
Body mass index, kg/m2 25.93.3 27.63.7 28.74.4 0.001
HDL cholesterol, mmol/L 1.40.4 1.30.4 1.10.3 0.001
LDL cholesterol, mmol/L 4.61.0 4.61.0 4.31.1 0.003
Triglycerides, mmol/L 1.3 (1.0 to 1.8) 1.6 (1.2 to 2.3) 2.0 (1.3 to 2.8) 0.001
Homocysteine, umol/L 11.2 (9.2 to 14.3) 12.2 (9.7 to 14.9) 11.1 (9.0 to 13.5) 0.47
Glomerular filtration rate, mL/min* 68.011.3 67.911.1 67.413.8 0.60
Prievious cardiovascular disease, % 17 23 31 0.001
Markers of endothelial dysfunction and
chronic low-grade inflammation
vWF, % 106 (90 to 131) 115 (93 to 150) 148 (108 to 176) 0.001
sVCAM-1, ng/mL 1316377 1363420 1497540 0.001
Endothelial dysfunction z score, SD 0.230.85 0.050.93 0.341.15 0.001†
CRP, mg/L 1.30 (0.84 to 1.98) 2.11 (1.03 to 3.05) 2.43 (1.63 to 356) 0.001
sICAM-1, ng/mL 448123 489166 520195 0.001
Inflammation z score, SD 0.290.87 0.071.01 0.321.05 0.001‡
Data are meanSD or median (interquartile range). Mean SD scores (z scores) for markers of endothelial dysfunction and chronic
low-grade inflammation were created. For each subject, each variable was expressed as SDs of difference from the population mean,
which was calculated using all available data on the separate markers (n608 and 610 of 631	 for the endothelial dysfunction and
inflammation z scores, respectively). The z scores were calculated as the mean of these SD scores as follows: (1) endothelial
dysfunction z score  vWFsVCAM-1	/2; (2) inflammation z score  CRPsICAM-1	/2.
*According to the Modification of Diet in Renal Disease Study Group (MDRD) formula; †IGM vs NGM, P0.050; T2D vs IGM,
P0.0001; T2D vs NGM, P0.0001; ‡IGM vs NGM, P0.0001; T2D vs IGM, P0.021; T2D vs NGM, P0.0001.
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Figure 1. Cardiovascular survival (Kaplan–Meier method) according to markers of endothelial dysfunction and chronic low-grade
inflammation.
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Endothelial Dysfunction and Low-Grade
Inflammation Explain Much of the Cardiovascular
Mortality Risks Associated With T2D
Table II (available online at http://atvb.ahajournals.org) shows that
T2D was significantly associated with both cardiovascular and
all-cause mortality (2.74 [1.52 to 4.92] and 1.90 [1.34 to 2.69],
respectively), but IGM was not (1.25 [0.63 to 2.48] and 1.05 [0.70
to 1.56], respectively). Adjustment for the endothelial dysfunction
and low-grade inflammation z scores reduced the magnitude of the
association between T2D and cardiovascular mortality by 34% and
25%, respectively. Together, the z scores explained 43% of the
cardiovascular mortality risk associated with T2D (Table II; Figure
2). Results were similar when adjusted for the individual markers
instead of the endothelial dysfunction and inflammation z scores
(data not shown). Adjustment for traditional risk factors such as
hypertension, smoking, LDL cholesterol, body mass index, and
previous cardiovascular disease did not reduce the magnitude of the
association between T2D and cardiovascular mortality to this extent
(Table II).
Additional Analyses
Exclusion of individuals with impaired fasting glucose (n29)
did not affect the results (data not shown). The following
additional adjustments also did not materially affect our results:
analyses using waist or waist-to-hip ratio instead of body mass
index; analyses using the creatinine clearance according to the
Cockcroft–Gault criteria instead of the glomerular filtration rate;
and analyses that adjusted for microalbuminuria. Hazard ratios
remained constant over time (data not shown).
Discussion
Our study on endothelial dysfunction and low-grade inflamma-
tion in individuals without and with T2D had 3 main findings.
First, T2D was associated with both endothelial dysfunction and
low-grade inflammation, whereas IGM was associated only with
low-grade inflammation. These findings were independent of
other risk factors that accompany T2D or IGM. Second, endo-
thelial dysfunction and low-grade inflammation were associated
with greater risks of cardiovascular mortality, especially in T2D.
Third, T2D-associated endothelial dysfunction and low-grade
Figure 1. Continued.
TABLE 2. Associations Between Glucose Tolerance Status and the Endothelial Dysfunction and Inflammation z Scores
Model Added Variables
Regression Coefficient (ß)
Endothelial Dysfunction z Score Inflammation z Score
T2D vs NGM IGM vs NGM T2D vs NGM IGM vs NGM
1 Age and sex 0.521*† 0.153 0.594*‡ 0.357*
(0.337 to 0.705) (0.034 to 0.341) (0.409 to 0.779) (0.168 to 0.545)
2 Age, sex, hypertension, smoking, LDL cholesterol, 0.395*† 0.098 0.490* 0.313§
and prior cardiovascular disease (0.204 to 0.585) (0.091 to 0.286) (0.301 to 0.678) (0.127 to 0.500)
3 Model 2 and body mass index 0.350*‡ 0.080 0.390* 0.265§
(0.155 to 0.546) (0.110 to 0.269) (0.198 to 0.583) (0.079 to 0.451)
4 Model 2 and HDL cholesterol 0.360*‡ 0.080 0.392* 0.267§
(0.164 to 0.556) (0.080 to 0.270) (0.200 to 0.584) (0.082 to 0.452)
5 Model 2 and triglycerides 0.391*‡ 0.100 0.384* 0.269§
(0.191 to 0.591) (0.090 to 0.291) (0.188 to 0.579) (0.083 to 0.455)
6 Model 2 and homocysteine 0.414*‡ 0.083 0.496* 0.309§
(0.225 to 0.603) (0.104 to 0.269) (0.307 to 0.685) (0.122 to 0.495)
7 Model 2 and glomerular filtration rate  0.431*‡ 0.097 0.486* 0.325 §
(0.243 to 0.618) (0.090 to 0.283) (0.294 to 0.677) (0.134 to 0.515)
Regression coefficients ß and 95% CIs were obtained by linear regression analysis with endothelial dysfunction or inflammation z scores as dependent variables
and IGM or T2D as independent variables. Model 1: Adjusted for stratification variables; model 2: adjusted for stratification variables and hypertension, smoking, and
previous cardiovascular disease; models 3 through 6, plus adjusted for other potential confounders. The same analysis was also performed with NGM and T2D as
independent variables to compare T2D with IGM.
*P0.0001 vs NGM; †P0.0001 vs IGM; ‡P0.025 vs IGM; §P0.025 vs NGM; other P values0.1.
According to the MDRD formula.
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inflammation explained 43% of the greater cardiovascular
mortality risk conferred by T2D.
Strengths of our study include its population-based design, the
long follow-up (up to 13 years), the limited loss to follow-up,
and the extensive characterization of participants at baseline. In
addition, the results were robust and consistent across the
markers of endothelial dysfunction and inflammation used.
As expected, T2D was associated with both endothelial dysfunc-
tion and low-grade inflammation.12,18,24 In contrast, IGM was
associated only with low-grade inflammation, which is in agree-
ment with previous studies that have shown a much clearer
association of IGM with low-grade inflammation than with endo-
thelial dysfunction,25–29 which, to some extent, appears to depend
on the endothelial function marker used.28–36 Together, these data
suggest that endothelial dysfunction is not universal in IGM and
may depend on other factors not identified in these studies.
Endothelial dysfunction and low-grade inflammation
were associated with higher risks of cardiovascular mor-
tality, consistent with previous studies.7,18 –20,37 Impor-
tantly, we show that for endothelial dysfunction, these
associations were stronger in diabetic than in nondiabetic
individuals, were independent of other cardiovascular risk
factors, remained present during up to 13 years of follow-
up, and appeared mutually independent,7,37 indicating that
TABLE 3. Hazard Ratios of Cardiovascular and All-Cause Mortality Associated With Markers of Endothelial
Dysfunction and Chronic, Low-Grade Inflammation, and With Potential Confounders
Contrast for Which Hazard
Ratio Is Presented
Cardiovascular Mortality
Hazard Ratio
(95% CI) n66
All-Cause Mortality
Hazard Ratio
(95% CI) n174
Markers of endothelial dysfunction and
chronic low-grade inflammation
vWF, % Per SD increase* T2D 1.31 (1.00 to 1.72) 1.10 (0.91 to 1.34)
No T2D 1.23 (0.88 to 1.73) 1.26 (1.04 to 1.54)
sVCAM-1, ng/mL High vs low† T2D 2.87 (1.42 to 5.80) 2.16 (1.37 to 3.41)
No T2D 1.05 (0.51 to 2.17) 0.72 (0.46 to 1.14)
Endothelial dysfunction z score, SD Per SD increase* T2D 1.87 (1.43 to 2.45) 1.41 (1.16 to 1.72)
No T2D 1.23 (0.86 to 1.75) 1.09 (0.87 to 1.36)
CRP, mg/L Doubling‡ 1.63 (1.04 to 2.57) 1.27 (0.97 to 1.67)
sICAM-1, ng/mL Per SD increase* 1.28 (1.09 to 1.50) 1.22 (1.08 to 1.37)
Inflammation z score, SD Per SD increase* 1.43 (1.17 to 1.77) 1.27 (1.10 to 1.47)
Potential confounders
Male sex, % Yes vs no 1.46 (0.90 to 2.38) 1.62 (1.20 to 2.19)
Age, y Per SD increase* 2.22 (1.65 to 2.98) 1.93 (1.61 to 2.29)
T2D, % T2D vs NGM 2.74 (1.52 to 4.92) 1.90 (1.34 to 2.69)
IGM, % IGM vs NGM 1.25 (0.63 to 2.48) 1.05 (0.70 to 1.56)
Hemoglobin A1c, % of hemoglobin Per SD increase* 1.12 (0.89 to 1.42) 1.17 (1.00 to 1.36)
Hypertension, % Yes vs no 1.97 (1.17 to 3.29) 1.58 (1.16 to 2.15)
Diastolic blood pressure, mm Hg High vs low† 1.08 (0.61 to 1.91) 1.10 (0.78 to 1.57)
Systolic blood pressure, mm Hg High vs low† 1.66 (1.00 to 2.75) 1.32 (0.96 to 1.82)
Current smokers, % Yes vs no 1.62 (0.93 to 2.83) 1.65 (1.18 to 2.30)
Body mass index, kg/m2 Per SD increase* 1.11 (0.87 to 1.42) 1.13 (0.97 to 1.32)
HDL cholesterol, mmol/L Per SD decrease* 1.18 (0.85 to 1.65) 1.05 (0.88 to 1.25)
LDL cholesterol, mmol/L Per SD increase* 1.12 (1.08 to 1.17) 1.02 (0.88 to 1.18)
Triglycerides, mmol/L Per SD increase* 1.16 (0.91 to 1.48) 1.18 (1.05 to 1.32)
Homocysteine, umol/L Per SD increase* 1.09 (0.93 to 1.29) 1.05 (0.92 to 1.19)
Glomerular filtration rate, mL/min§ Per SD decrease* 1.58 (1.22 to 2.05) 1.32 (1.12 to 1.57)
Previous cardiovascular disease Yes vs no 2.25 (1.37 to 3.70) 1.74 (1.26 to 2.38)
Hazard ratios and 95% CIs were obtained by Cox regression analysis after adjustment for age, sex, and glucose tolerance status,
except when analyses were stratified for glucose tolerance status because of interaction between glucose tolerance status and
endothelial dysfunction, or when glucose tolerance status was the variable under consideration.
*SDs for vWF, 67.6%; for endothelial dysfunction z score, 1; for sICAM-1, 162.9 ng/mL; for inflammation z score, 1; for age, 7.2
years; for hemoglobin A1c, 1.3%; for body mass index, 4.0 kg/m2; for HDL cholesterol, 0.4 mmol/L; for LDL cholesterol, 1.1 mmol/L;
for triglycerides, 1.3 mmol/L; for homocysteine, 5.8 mol/L; and for glomerular infiltration rate, 12.1 mL/min.
†sVCAM-1 high 1485 ng/mL, low 1484 ng/mL; diastolic blood pressure high 90 mm Hg, low 90 mm Hg; systolic blood
pressure high 140 mm Hg, low 140 mm Hg.
‡Data on CRP were log transformed before analysis because of its nonlinear association with mortality.
§According to the MDRD formula.
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they may represent largely distinct pathways of disease
and therefore distinct targets for intervention.
Both endothelial dysfunction and low-grade inflammation
appeared to explain parts of the increased mortality risks
associated with T2D. However, the role of endothelial dysfunc-
tion seems especially relevant because of its interaction with
T2D. Together, our data suggest that treatments to improve the
cardiovascular prognosis of individuals with T2D should focus
on improving endothelial function and decreasing chronic in-
flammation. The causes of endothelial dysfunction and low-
grade inflammation in T2D remain incompletely understood and
may include not only obesity, hypertension, dyslipidemia, insu-
lin resistance, and hyperglycemia (the metabolic syndrome), but
also advanced glycation end products.12 In addition, endothelial
dysfunction and low-grade inflammation may precede and
contribute to the occurrence of T2D.38
In the present study, IGM was not clearly associated with an
increased mortality risk (although the confidence limits show that
we could not exclude any such associations with great certainty),
and we therefore could not test the influence of endothelial dys-
function or low-grade inflammation. Other reports from the Hoorn
Study have shown that 2-hour postload plasma glucose concentra-
tions do predict cardiovascular and all-cause mortality but mostly in
the diabetic range.2,39 Other studies on IGM and risk of mortality
have reported inconsistent results.40–46
Our study has several limitations. First, its relatively small
size and consequently limited power may have obscured more
subtle associations. Second, the incomplete assessment of endo-
thelial function and inflammatory activity may have increased
nondifferential misclassification, leading to an underestimation
of the hazard ratios presented here. However, our results were
robust and consistent with previous experience. Third, we used
sICAM-1 as a marker of inflammation, although sICAM-1 can
be regarded as a marker of both endothelial function and
inflammation.16,47 However, to classify sICAM-1 as a marker of
inflammation can be considered the most conservative alterna-
tive because sICAM-1 is not selectively derived from endothe-
lial cells but originates from leukocytes as well. However,
sICAM-1 upregulation is driven by inflammatory cytokines such
as tumor necrosis factor- and interleukin-8, resulting in the
activation of nuclear factor B.48 Importantly, additional analy-
ses showed that our conclusions remain unchanged when
sICAM-1 is classified as a marker of endothelial function (data
not shown). Fourth, we studied white individuals, and the results
therefore are not necessarily valid for other ethnicities. Fifth, an
assumption in the construction of the z scores is that its
components are equally important, which is not necessarily true.
Nevertheless, z scores have the considerable merit of increased
precision, as demonstrated by the smaller CIs of the z scores
compared with those of the individual markers and, possibly, of
increased validity because these z scores address various aspects
of endothelial dysfunction and inflammation, respectively. Fi-
nally, because traditional risk factors were measured only once,
we may, to some extent, have underestimated their associations
with mortality, although previous analyses from the Hoorn
Study have shown that traditional risk factors, even if measured
only once, do in fact predict mortality.49
In conclusion, we have shown that T2D is associated with
both endothelial dysfunction and low-grade inflammation,
whereas IGM is associated only with low-grade inflammation,
that endothelial dysfunction and low-grade inflammation are
associated with greater risks of cardiovascular mortality, espe-
cially in T2D, and that T2D-associated endothelial dysfunction
and low-grade inflammation can explain 43% of the higher
cardiovascular mortality risk conferred by T2D. These data
emphasize the necessity of randomized controlled trials of
strategies that aim to decrease cardiovascular disease risk by
improving endothelial function and decreasing low-grade in-
flammation, especially in T2D, for which endothelial dysfunc-
tion is particularly ominous and for which both endothelial
dysfunction and low-grade inflammation are highly prevalent.
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